Early Weight Loss and Other Factors Associated With Clinically Significant Weight Loss in Two Commercial Weight Loss...

Area of Science:

• Obesity research
• Behavioral science
• Clinical trials

Background:

• Two commercial weight loss programs (Medifast and OPTAVIA) utilizing meal replacements and behavioral support were evaluated.
• Identifying factors associated with achieving clinically significant weight loss (≥5% or ≥10%) is crucial for program optimization.

Purpose of the Study:

• To assess demographic, anthropometric, behavioral, and lifestyle factors linked to achieving ≥5% or ≥10% weight loss at 16 weeks.
• To determine the predictive value of early weight loss thresholds (2 and 4 weeks) on long-term weight loss success.

Main Methods:

• Secondary analysis of a clinical trial involving 124 adults randomized to Medifast or OPTAVIA.
• Multivariable logistic regression was employed to identify significant predictors of weight loss at 16 weeks.
• Early weight loss percentages at weeks 2 and 4 were analyzed as potential indicators of success.

Main Results:

• Achieving ≥5% weight loss at 16 weeks was associated with age, education, ≥1% weight loss by week 2, ≥2% weight loss by week 4, support contact frequency, and adherence through week 4.
• Losing ≥2% body weight by week 4 increased the odds of achieving ≥5% weight loss by week 16 by 24.6 times.
• Factors associated with ≥10% weight loss at 16 weeks included age, the OPTAVIA program, ≥3% weight loss by week 4, and adherence through week 4.
• Losing ≥3% body weight by week 4 increased the odds of achieving ≥10% weight loss by week 16 by 19.4 times.

Conclusions:

• Early weight loss, particularly by week 4, is the strongest predictor of achieving clinically significant weight loss at 16 weeks in these commercial programs.
• Identifying individuals at risk for poor weight loss early on can guide interventions like intensified counseling.
• These findings support the use of early weight loss as a marker for tailoring support in weight management programs.